Table 3.
Acute and late toxicities. Details on hematologic, extra-hematologic toxicity and long term complications (secondary neoplasia) after bendamustine-based therapy. Abbreviations: UTI, urinary tract infections, CMV, cytomegalovirus, VZV, varicella zoster virus.
| Adverse Event (n. of Analyzed Patients) * | n. (%) |
|---|---|
| Hematologic | |
| Neutropenia (%) | |
| No | 78 (43.6) |
| Yes (any grade) | 101 (56.4) |
| Grade < 3 | 22 (12.3) |
| Grade ≥ 3 | 79 (43.5) |
| Thrombocytopenia (%) | |
| No | 100 (55.9) |
| Yes (any grade) | 79 (44.1) |
| Grade < 3 | 58 (32.4) |
| Grade ≥ 3 | 21 (11.7) |
| Anemia (%) | |
| No | 74 (41.3) |
| Yes (any grade) | 105 (58.7) |
| Grade < 3 | 84 (46.9) |
| Grade ≥ 3 | 21 (11.7) |
| Extra-hematologic | |
| Patients who had infections (%) | |
| No | 115 (64.2) |
| Yes | 64 (35.7) |
| Infectious events (%) | |
| Respiratory infections | 25 (14) |
| Fever of unknown origin (FUO) | 13 (7.3) |
| Gastrointestinal infections | 7 (3.9) |
| VZV cutaneous reactivation | 6 (3.3) |
| UTI | 5 (2.8) |
| Oral infections | 5 (2.8) |
| Sepsis | 5 (2.8) |
| CMV reactivation | 2 (1.1) |
| Febrile neutropenia | 2 (1.1) |
| Other | 11 (6.1) |
| Infectious etiology (%) | |
| Bacterial | 27 (15.1) |
| Viral | 14 (7.8) |
| Fungal | 6 (3.3) |
| Unknown | 34 (19) |
| Other toxicities (%) (177) | |
| No | 126 (71.2) |
| Autoimmune disorder (e.g., AIHA) | 4 (2.3) |
| Skin toxicity | 15 (8.5) |
| Other | 32 (18.1) |
| Admission-requiring AEs (%) | |
| No | 148 (82.7) |
| Yes | 31 (17.3) |
| Length of stay (days [median]) | 10.00 [6.00, 20.00] |
| Cause of admission (%) | |
| Sepsis | 9 (5) |
| Fever of unknown origin (FUO) | 5 (2.8) |
| Pneumonia | 4 (2.2) |
| Gastrointestinal complications |
3 (1.7) |
| Cardiovascular complications | 3 (1.7) |
| Acute kidney injury | 2 (1.1) |
| CMV reactivation | 1 (0.6) |
| Steven-Johnson syndrome | 1 (0.6) |
| Other complications | 3 (1.7) |
| Second cancer (%) | |
| No | 139 (77.7) |
| Yes | 40 (22.3) |
| Second cancer type (%) | |
| Hematologic cancer | 10 (5.6) |
| Urogenital cancer | 8 (4.5) |
| Gastrointestinal cancer | 8 (4.5) |
| Skin cancer | 7 (3.9) |
| Lung cancer | 3 (1.7) |
| Breast cancer | 1 (0.6) |
| Other | 3 (1.7) |
* Number of analyzed patients is shown where different from total numbers of patients.